CDNA - CareDx, Inc
| Previous Close | 21.21 |
| Open | 21.41 |
| Bid | 17.00 x 800 |
| Ask | 0.00 x 2200 |
| Day's Range | 21.10 - 22.07 |
| 52 Week Range | 18.75 - 41.27 |
| Volume | 946,895 |
| Avg. Volume | 801,714 |
| Market Cap | 903.462M |
| Beta (3Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.20 |
- Insider Monkey
Is CareDx, Inc. (CDNA) A Good Stock To Buy?
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was CareDx, Inc. (NASDAQ:CDNA). CareDx, Inc. (NASDAQ:CDNA) was in 22 hedge […]
- GlobeNewswire
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif., Nov. 19, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- Simply Wall St.
Did The Underlying Business Drive CareDx's (NASDAQ:CDNA) Lovely 417% Share Price Gain?
CareDx, Inc (NASDAQ:CDNA) shareholders might be concerned after seeing the share price drop 27% in the last month. But...
- Thomson Reuters StreetEvents
Edited Transcript of CDNA earnings conference call or presentation 31-Oct-19 8:30pm GMT
Q3 2019 CareDx Inc Earnings Call
- GlobeNewswire
CareDx at ASN Kidney Week
BRISBANE, Calif., Nov. 06, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire
CareDx Advances Patient Care with AlloSure 3.0
CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces the launch of AlloSure 3.0, the next iteration in continued transplant patient-focused improvements. CareDx continues to drive innovation in the field. CareDx has new data showing AlloSure provides more in-depth insights into patients with TCMR1A and borderline rejection.
- Zacks
All You Need to Know About CareDx (CDNA) Rating Upgrade to Strong Buy
CareDx (CDNA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Benzinga
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
- GlobeNewswire
CareDx Reports Third Quarter 2019 Results
BRISBANE, Calif., Oct. 31, 2019 -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically.
- Insider Monkey
Were Hedge Funds Right About Flocking Into CareDx, Inc. (CDNA)?
Is CareDx, Inc. (NASDAQ:CDNA) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. […]
- Zacks
Top Ranked Momentum Stocks to Buy for October 18th
Top Ranked Momentum Stocks to Buy for October 18th
- GlobeNewswire
CareDx to Announce Third Quarter 2019 Financial Results on October 31st, 2019
BRISBANE, Calif., Oct. 17, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- Simply Wall St.
We're Excited To See How CareDx (NASDAQ:CDNA) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- Zacks
CareDx, Inc (CDNA) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in CareDx, Inc (CDNA).
- GlobeNewswire
CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor
CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has filed a patent infringement suit against Eurofins Viracor, Inc., in the United States District Court for Delaware. CareDx is asserting U.S. Patent No. 8,703,652, which is exclusively licensed to CareDx from Stanford University. This patent covers non-invasive monitoring of organ transplant rejection through cell-free DNA analysis. CareDx is seeking all available remedies, including damages and injunctive relief.
- GlobeNewswire
CareDx Adds HistoMap To Testing Portfolio
CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a strategic partnership with NanoString to develop HistoMap, a gene expression profiling (GEP) solution to identify allograft rejection in transplant biopsy tissue. Seattle-based NanoString (NSTG) is a leading provider of life science tools for translational research and molecular diagnostic products.
- GlobeNewswire
CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication
BRISBANE, Calif., Sept. 23, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire
CareDx Launches AlloSeq® Tx 17 at ASHI/BANFF Meeting
BRISBANE, Calif., Sept. 20, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire
First Patient Enrolled in Landmark CareDx OKRA Registry
BRISBANE, Calif., Sept. 18, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire
CareDx to Participate in the Cantor Fitzgerald Global Healthcare Conference
BRISBANE, Calif., Sept. 17, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire
CareDx launches AlloSeq® cfDNA at ESOT 2019
BRISBANE, Calif., Sept. 12, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- Simply Wall St.
Who Has Been Selling CareDx, Inc (NASDAQ:CDNA) Shares?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
- GlobeNewswire
CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 11, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire
CareDx Acquires XynManagement
BRISBANE, Calif., Aug. 28, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
- GlobeNewswire
Chris Cournoyer Joins CareDx Board of Directors
BRISBANE, Calif., Aug. 27, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically.
